Quick Answer
Lyell Immunopharma, Inc. reported Cash and Equivalents of $60.18 million for fiscal year 2025.
Lyell Immunopharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $60.18M | -43.0% |
| 2024 | $105.60M | -27.5% |
| 2023 | $145.65M | +17.9% |
| 2022 | $123.55M | -58.0% |
| 2021 | $293.83M | +109.3% |
| 2020 | $140.41M | +45.2% |
| 2019 | $96.67M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $123.58M | +23.2% | +25.1% |
| June 30, 2025 | $98.80M | -25.9% | -17.9% |
| March 31, 2025 | $120.33M | -4.2% | +14.0% |
| December 31, 2024 | $105.60M | -27.5% | +5.3% |
| September 30, 2024 | $100.30M | -65.0% | -24.8% |
| June 30, 2024 | $133.42M | -40.5% | +6.2% |
| March 31, 2024 | $125.65M | +14.8% | -13.7% |
| December 31, 2023 | $145.65M | +17.9% | -49.1% |
- Lyell Immunopharma, Inc. showed a decrease of -43.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Lyell Immunopharma, Inc.’s cash and equivalents has declined by 37.7% (from $96.67 million to $60.18 million).
- The most recent figure is from Lyell Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: